RVMD

Rating neutralTentativeAI MemoPost-earnings T+3

Revolution Medicines

As of 2026-05-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

RASolve 308 Phase 3 initiation in first-line KRAS G12D NSCLC [#10-Q-2026-05-06] • 2026-06-30

Base target: $132 / p=1% prob

Biggest risk

The bear case is that the earnings follow-up did not add a fresh upside unlock beyond the already known trial win, while Q1 net loss widened to $453.8 million and heavy spend across daraxonrasib and zoldonrasib leaves execution, timing and regulatory conversion risk high. [#10-Q-2026-05-06]

Invalidation

Break below $105 or thesis failure.

What would change my mind?

The bull case remains that the RASolute 302 survival data materially advanced daraxonrasib toward a filing path and that the May 6 Q1 update kept the clinical and funding story intact, with roughly $2.1 billion of April net proceeds added after the Q1 balance-sheet date. [#10-Q-2026-05-06]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-08

Base target

$132

p=1%

Bull target

$165

p=0%

Bear target

$105

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 cash runway improved, but burn and filing execution remain the post-earnings focus [#8-K-2026-05-06]
The bull case remains that the RASolute 302 survival data materially advanced daraxonrasib toward a filing path and that the May 6 Q1 update kept the clinical and funding story intact, with roughly $2.1 billion of April net proceeds added after the Q1 balance-sheet date.
[#10-Q-2026-05-06]

BearKey bullets

Clinical success still has to convert into an NDA and approval; the 10-Q notes FDA/CNPV timing and acceptance are not assured even if the company intends to use RASolute 302 in a future filing.
[#10-Q-2026-05-06]
Execution risk is elevated because Revolution is running or planning multiple registrational studies at once, including RASolute 303/304/305 and RASolve 301/308.

WatchKey bullets

RASolve 308 Phase 3 initiation in first-line KRAS G12D NSCLC [#10-Q-2026-05-06]

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $132 (p=1%)

Target spread vs base: +25% / -20%

Scenario probabilities

Bull Target: $165 (p=0%)Base Target: $132 (p=1%)Bear Target: $105 (p=0%)

Commentary

Primary-source support is adequate for a cautious post-earnings monitoring view because the May 6 8-K confirms the Q1 results release and the 10-Q provides the operating and cash details. The follow-up evidence is still limited: the packet does not provide a concrete earnings surprise, guidance revision, or T+3 analyst revision set, and the peer set is generic for a concentrated RAS oncology developer. News tone remains helped by the prior daraxonrasib clinical update, but missing revision and market-reaction evidence should not be treated as positive confirmation.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 cash runway improved, but burn and filing execution remain the post-earnings focus [#8-K-2026-05-06]

Scenarios

Bull Target (Scenario probability)

$165 / p=0% prob

Base Target (Scenario probability)

$132 / p=1% prob

Bear Target (Scenario probability)

$105 / p=0% prob

Analysis 2026-05-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.56

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-30
RASolve 308 Phase 3 initiation in first-line KRAS G12D NSCLC [#10-Q-2026-05-06]
The 10-Q says Revolution expects to initiate RASolve 308, a Phase 3 registrational trial for zoldonrasib in first-line metastatic RAS G12D NSCLC, in the first half of 2026; actual initiation would support the broader RAS(ON) platform beyond daraxonrasib, but the memo should treat this as an execution checkpoint rather than a confirmed value inflection. [#10-Q-2026-05-06]
Prob 68.00% • Move 5.00% • Priced-in 58.00%
EVENT2026-12-31
Daraxonrasib regulatory submission path after pivotal RASolute 302 win [#10-Q-2026-05-06]
The Q1 filing says daraxonrasib's Phase 3 RASolute 302 showed median overall survival of 13.2 months versus 6.7 months for chemotherapy with a hazard ratio of 0.40, and management intends to use the dataset in a future NDA/CNPV pathway; regulatory filing progress is now the key de-risking event. [#10-Q-2026-05-06]
Prob 72.00% • Move 10.00% • Priced-in 68.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Q1 cash runway improved, but burn and filing execution remain the post-earnings focus [#8-K-2026-05-06]
2026-12-31
Revolution's May 6 8-K confirms the company announced Q1 2026 financial results, and the Q1 filing shows $1.9 billion of cash, cash equivalents and marketable securities at quarter-end plus about $2.1 billion of net proceeds from April 2026 offerings. That funding supports multiple registrational programs, but Q1 net loss was $453.8 million and investors still need evidence that elevated daraxonrasib and zoldonrasib spend converts into filing, approval and launch progress. [#8-K-2026-05-06] [#10-Q-2026-05-06]
Prob 82% • Move 3% • Priced-in 72%

Risks

Clinical success still has to convert into an NDA and approval; the 10-Q notes FDA/CNPV timing and acceptance are not assured even if the company intends to use RASolute 302 in a future filing. [#10-Q-2026-05-06]
Execution risk is elevated because Revolution is running or planning multiple registrational studies at once, including RASolute 303/304/305 and RASolve 301/308. [#10-Q-2026-05-06]
Expense intensity is high: Q1 net loss was $453.8 million, and third-party R&D spending for daraxonrasib and zoldonrasib increased materially year over year. [#10-Q-2026-05-06]
The peer set in the packet is loose and lacks enough direct operating comparators, which reduces confidence in relative-valuation arguments and makes sentiment more dependent on single-program milestones.

Peers

Symbol	Summary
AMGN	Amgen is the closest candidate in the packet for a marketed KRAS benchmark because Lumakras gives investors a real-world frame for RAS-targeted oncology commercialization, although Amgen is far more diversified and mature than RVMD.
ONC	BeOne Medicines is a closer oncology-development comp than broad biopharma names on pipeline intensity, but its portfolio is still much broader than RVMD's concentrated RAS thesis, so the comparison is only partial.
GILD	Gilead is mainly a scale and oncology-commercialization reference rather than a direct operating peer; the packet's peer set is therefore too loose to support high-conviction relative valuation.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-08

Loading AI feed…

Symbol

Summary

AMGN

Amgen is the closest candidate in the packet for a marketed KRAS benchmark because Lumakras gives investors a real-world frame for RAS-targeted oncology commercialization, although Amgen is far more diversified and mature than RVMD.

ONC

BeOne Medicines is a closer oncology-development comp than broad biopharma names on pipeline intensity, but its portfolio is still much broader than RVMD's concentrated RAS thesis, so the comparison is only partial.

GILD

Gilead is mainly a scale and oncology-commercialization reference rather than a direct operating peer; the packet's peer set is therefore too loose to support high-conviction relative valuation.